The landscape of hepatitis C (HCV) management has undergone a radical transformation over the last decade, yet the public health…
Read More
The oral exposure challenge in PROTACs: What drug developers need to solve early
The landscape of modern pharmacology shifted fundamentally in May 2026, when the U.S. Food and Drug Administration (FDA) granted approval…
Read More
Merck and Moderna’s cancer vaccine is customized for each patient’s tumor
The landscape of oncology is currently undergoing a paradigm shift as pharmaceutical giants Merck & Co. and Moderna transition from…
Read More
2026 PharmSci 360 adds tracks on research credibility and post-animal drug development
The American Association of Pharmaceutical Scientists (AAPS) has announced a strategic shift in the programming for its flagship 2026 PharmSci…
Read More
Cancer vaccine borrows COVID immune memory to activate T cells against tumors in mice
The global landscape of immunology has been irrevocably altered by the COVID-19 pandemic, leaving behind a massive, persistent, and highly…
Read More
DEA targets synthetic kratom-related products mitragynine pseudoindoxyl, MGM-15, and MGM-16 for temporary controls in Schedule I
The United States Drug Enforcement Administration (DEA) has officially moved to curtail the proliferation of highly potent, synthetic derivatives associated…
Read More
New cell imaging method reveals hidden enzyme activity
For decades, the field of molecular biology has grappled with a significant limitation in cellular visualization: the inability to accurately…
Read More
After decades of trial failures in chemotherapy-linked neuropathy, psilocybin shows promise in preventing it in mice
For millions of cancer patients worldwide, the life-saving potential of chemotherapy is frequently tempered by a debilitating, long-term side effect:…
Read More
Pharma commercial vendor selection still runs on word of mouth. A Harvard MBA student aims to change that with Rx Almanac.
The pharmaceutical industry, a sector defined by rigorous clinical validation and data-driven R&D, paradoxically relies on archaic, informal methods when…
Read More
The 50 best-funded biotech companies of 2026
The biotechnology sector in 2026 continues to demonstrate remarkable resilience and a sustained appetite for high-risk, high-reward innovation, even as…
Read More
